e-Article
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
Document Type
Article
Author
Baigent, Colin; Emberson, JonathanR.; Haynes, Richard; Herrington, William G.; Judge, Parminder; Landray, Martin J.; Mayne, Kaitlin J.; Ng, Sarah Y.A.; Preiss, David; Roddick, Alistair J.; Staplin, Natalie; Zhu, Doreen; Anker, Stefan D.; Bhatt, Deepak L.; Brueckmann, Martina; Butler, Javed; Cherney, David Z.I.; Green, Jennifer B.; Hauske, Sibylle J.; Haynes, Richard; Heerspink, Hiddo J.L.; Herrington, William G.; Inzucchi, Silvio E.; Jardine, Meg J.; Liu, Chih-Chin; Mahaffey, Kenneth W.; McCausland, Finnian R.; McGuire, Darren K.; McMurray, John J.V.; Neal, Bruce; Neuen, Brendon L.; Packer, Milton; Perkovic, Vlado; Sabatine, Marc S.; Solomon, Scott D.; Vaduganathan, Muthiah; Wanner, Christoph; Wheeler, David C.; Wiviott, Stephen D.; Zannad, Faiez
Source
The Lancet; November 2022, Vol. 400 Issue: 10365 p1788-1801, 14p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of the trials recruiting patients with and without diabetes were designed to assess outcomes separately in patients without diabetes.